ArticleContemporary clinical dentistry
CD34 Angiogenesis Marker in Oral Squamous Cell Carcinoma: An Immunohistochemical Study.
Article in Contemporary clinical dentistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Angiogenesis is recognized as a predominant factor for tumor growth and metastasis. Use of biomarkers to target tumor holds a promising treatment strategy and to assess prognosis. Objectives: To assess angiogenic activity by analyzing CD34 microvascular density (MVD) count in different histologic grades of oral squamous cell carcinoma (OSCC). Materials and Methods: Sixty archival samples are categorized in four groups. Immunohistochemical method with anti-CD34 was used for analyzing MVD. Results: The mean count of MVD is higher in OSCC than in normal mucosa and also significant among different histologic grades. Highly significant correlation is observed among different groups of OSCC samples. Conclusion: CD34 shows a promising result in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.